Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plegridy vs Rebif PK in Healthy Volunteers
NCT02269930Phase 1Completed
- Sponsor
- Biogen
- Start
- Oct 2014
- Primary completion
- Dec 2014
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of interferon beta in multiple sclerosis (MS), sponsored by Biogen. Primary endpoint: Area under the concentration-time curve from 0 to 336 hours. Started Oct 2014; status: completed.
02
Drugs
interferon beta
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02269930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02269930.